Related Experiment Videos

Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients

D Leonardis1, G Basta, F Mallamaci

  • 1Renal and Transplantation Unit OO.RR. and CNR-IBIM, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension of Reggio Calabria, Italy.

Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
|April 8, 2011
PubMed

Insights

Soluble RAGE (sRAGE) is inversely associated with left ventricular hypertrophy (LVH) in chronic kidney disease (CKD) patients. Higher sRAGE levels may protect against LVH progression in this population.

Area of Science:

  • Cardiology
  • Nephrology
  • Biochemistry

Background:

  • The advanced glycation end product decoy receptor (sRAGE) is implicated in heart disease.
  • sRAGE levels are elevated in patients with chronic kidney disease (CKD).
  • The relationship between sRAGE and left ventricular hypertrophy (LVH) in CKD patients is not well understood.

Purpose of the Study:

  • To investigate the association between plasma sRAGE and LVH in patients with CKD.

Main Methods:

  • 142 CKD patients and 49 healthy controls were enrolled.
  • Plasma sRAGE levels were measured.
  • Echocardiography was used to assess LVH, including left ventricular mass index (LVMI) and mean wall thickness (MWT).
  • Statistical analyses included covariance and logistic regression.

Main Results:

  • Plasma sRAGE was significantly higher in CKD patients compared to controls.
  • sRAGE showed a significant inverse relationship with LVMI and MWT in CKD patients, but not in controls.
  • A 1-unit increase in sRAGE was associated with an 82% decrease in the odds of LVH in CKD patients.

Conclusions:

  • sRAGE serves as an inverse marker of LVH in CKD patients.
  • The RAGE pathway may be a causal factor in LVH development in CKD.
  • sRAGE may attenuate LVH in CKD patients, suggesting potential therapeutic implications.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...